Mochida Pharmaceutical Co., Ltd.

Tokyo Stock Exchange 4534.T

Mochida Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending March 31, 2024: USD -49.42 M

Mochida Pharmaceutical Co., Ltd. Operating Cash Flow is USD -49.42 M for the year ending March 31, 2024, a -189.98% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Mochida Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending March 31, 2023 was USD 54.92 M, a -10.36% change year over year.
  • Mochida Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending March 31, 2022 was USD 61.28 M, a -26.23% change year over year.
  • Mochida Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending March 31, 2021 was USD 83.06 M, a -4.44% change year over year.
  • Mochida Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending March 31, 2020 was USD 86.92 M, a -23.30% change year over year.
Key data
Date Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid
Market news
Loading...
SV Wall Street
Tokyo Stock Exchange: 4534.T

Mochida Pharmaceutical Co., Ltd.

CEO Mr. Naoyuki Mochida
IPO Date Jan. 1, 2001
Location Japan
Headquarters 1-1, Ichigaya-Honmura cho
Employees 1,522
Sector Healthcare
Industries
Description

Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.

Similar companies

4521.T

Kaken Pharmaceutical Co., Ltd.

USD 28.07

-2.08%

4540.T

Tsumura & Co.

USD 28.56

1.43%

4530.T

Hisamitsu Pharmaceutical Co., Inc.

USD 27.93

-1.88%

4516.T

Nippon Shinyaku Co., Ltd.

USD 25.74

-0.03%

StockViz Staff

February 8, 2025

Any question? Send us an email